PIEN HOWARD H

Form 4 September 03, 2009

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB APPROVAL** OMB

3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per

response... 0.5

Check this box if no longer subject to Section 16.

Form 4 or Form 5 obligations

may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

Security

(Instr. 3)

(Print or Type Responses)

1. Name and Address of Reporting Person \* PIEN HOWARD H

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

(Middle)

3. Date of Earliest Transaction

MEDAREX INC [MEDX]

(Month/Day/Year)

09/01/2009

\_X\_\_ Director 10% Owner X\_ Officer (give title Other (specify

(Check all applicable)

below) Pres., CEO & Chair. of the Brd

C/O MEDAREX, INC., 707 STATE ROAD

(Street)

(First)

4. If Amendment, Date Original

(Instr. 8)

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

(Instr. 4)

Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

PRINCETON, NJ 08540

(City) (State) (Zip) 1. Title of 2. Transaction Date 2A. Deemed

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D)

5. Amount of Securities Beneficially Owned Following

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial Ownership (T)

(Instr. 4)

Reported Transaction(s) (Instr. 3 and 4)

Code V Amount (D) Price

(Instr. 3, 4 and 5)

(A)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Execution Date, if

(Month/Day/Year)

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction Date 3A. Deemed 4. 5. Number of 6. Date Exercisable and 7. Title and Amount of Derivative Conversion (Month/Day/Year) Execution Date, if **Transaction**Derivative **Expiration Date Underlying Securities** Security or Exercise any Code Securities (Month/Day/Year) (Instr. 3 and 4)

### Edgar Filing: PIEN HOWARD H - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Dispo	ired (A) or osed of (D) : 3, 4, and				
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Stock Option (Right to Buy)	\$ 14.36	09/01/2009		D		500,000	<u>(1)</u>	06/28/2017	Common Stock	500,00
Stock Option (Right to Buy)	\$ 9.07	09/01/2009		D		270,000	<u>(2)</u>	03/02/2018	Common Stock	270,00
Stock Option (Right to Buy)	\$ 3.72	09/01/2009		D		270,000	(3)	03/04/2019	Common Stock	270,00
Restricted Stock Units	<u>(4)</u>	09/01/2009		D		90,000	<u>(5)</u>	<u>(7)</u>	Common Stock	90,000
Restricted Stock Units	<u>(4)</u>	09/01/2009		D		90,000	<u>(5)</u>	(8)	Common Stock	900,00
Restricted Stock Units	<u>(4)</u>	09/01/2009		D		192,360	<u>(6)</u>	<u>(9)</u>	Common Stock	192,36

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
r	Director	10% Owner	Officer	Other		
PIEN HOWARD H C/O MEDAREX, INC. 707 STATE ROAD PRINCETON, NJ 08540	X		Pres., CEO & Chair. of the Brd			

# **Signatures**

Beth A. Behrend,	09/03/2009		
Attorney-in-Fact	09/03/2009		
**Signature of Reporting Person	Date		

Reporting Owners 2

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This option was canceled in the merger in exchange for a cash payment of \$822,500.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- This option was canceled in the merger in exchange for a cash payment of \$1,872,450.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- This option was canceled in the merger in exchange for a cash payment of \$3,315,600.00, representing the difference between the exercise price of the option and the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (4) Each restricted stock unit represents a contingent right to receive one (1) share of Medarex, Inc. common stock.
- This restricted stock unit was canceled in the merger in exchange for a cash payment of \$1,440,000.00, based on the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- This restricted stock unit was canceled in the merger in exchange for a cash payment of \$3,077,760.00, based on the merger consideration (\$16 per share) pursuant to the Merger Agreement between issuer and Bristol-Myers Squibb.
- (7) Receipt of the restricted stock units was deferred until March 3, 2013.
- (8) Receipt of the restricted stock units was deferred until March 5, 2013.
- (9) Receipt of the restricted stock units was deferred until March 13, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.